Database

Startups

Main Industry
Biotechnology
Main Product/Service
Regene Biologics’ portfolio of offerings includes molecular biology services (such as gene editing, gene synthesis, DNA/RNA extraction and purification, library preparation, next‑generation sequencing), proteomics services (e.g., His‑tag protein purificat
Founded Year
2017
Unified Business No.
55787910
Status
Active
Number of Employees
0
Total Paid-in Capital
2,000,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Founded in 2012 and based in Hyderabad, India, Regene Biologics acts as an authorized dealer for both domestic and international biotechnology manufacturers and service providers, committed to delivering a comprehensive range of life‑science products and



More ↓

Similar Companies

BIOLEGEND TAIWAN INC.

1. Antibodies and Reagents
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort™
7. Non-Human Primate Antibodies
8. Recombinant Proteins, C

Taiwan Universe BioMedicine Inc.

Main Product
Innovative platform of enterovirus and influenza VLP vaccines
Promising option to combat viruses mutation
Provide a broad-spectrum prevention with better immunogenicity
Enable faster scaling-up